Charlotte D. Jacobs, MD

Cancer is a devastating, life-altering disease. As our technology and knowledge base for the treatment of carcinomas expand, however, more and more patients' lives are being spared or prolonged. Unfortunately, the quality of life for many of these

Two hundred sixty-five patients with head and neck cancer who had previously participated in either a fixed-dose, dose-titration, or dose-ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36-month